Equity Profile

VTRS

Viatris Inc.

Health CarePharmaceuticals$18.4B

Aug6Thu

Pre-Earnings Brief

UpcomingQ2-2026Pre-Market9:00 AM EDT

Company Snapshot

Viatris Inc. (VTRS) operates in the health care sector, focusing on pharmaceuticals....

Key Metrics to Watch

Earnings Per Share (EPS)

EPS is a key indicator of the company's profitability and performance, which investors will closely watch this quarter.

N/A

Revenue Growth

Revenue growth reflects the company's ability to expand its market presence and sales, critical for long-term success.

N/A

Wall Street expectations, options signals, track record, and call prep available with Pro.

VTRS Q2-2026 Earnings Preview

Context

Company Snapshot

Viatris Inc. (VTRS) operates in the health care sector, focusing on pharmaceuticals. The company plays a crucial role in providing access to medicines and improving patient health globally, which is increasingly important as healthcare needs evolve.

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

88%

Avg EPS Surprise

+6.19%

Avg Stock Reaction

+1.97%

Last Quarter Recap

In Q1-2026, Viatris reported an EPS of $0.59, exceeding estimates by 13.46%. The stock reacted positively, gaining 9.03% the following day.

Management Promises & Guidance

Continued focus on expanding access to medicines.
Commitment to cost management and operational efficiency.
Plans to enhance product offerings and market presence.

Expectations

Wall Street Expectations

Overall, expectations for Viatris are mixed, with some analysts anticipating continued earnings growth while others express concerns over revenue stability.

Bull Case

If Viatris can maintain its positive EPS surprises and show strong revenue growth, it could significantly boost investor confidence and stock performance.

Bear Case

Conversely, if the company fails to meet expectations or shows signs of declining revenue, it could lead to a sharp drop in stock price.

Expectations

Two Questions That Matter

The print will turn on these two things.

What will the EPS be for Q2-2026?

Given the company's history of beating EPS estimates, this number will be crucial for investor sentiment.

How is revenue growth tracking compared to previous quarters?

Investors will closely monitor revenue growth to assess the company's market performance and sustainability.

Edge

What the Street Is Missing

Why consensus could be wrong

The Street may underestimate Viatris's ability to leverage its product portfolio for growth, especially in emerging markets.

Supporting Evidence

The company has consistently beaten EPS estimates, indicating stronger operational performance than anticipated.

Options pricing suggests a larger move than historical averages, indicating potential for significant stock movement.

Recent trends in the pharmaceutical sector show increasing demand for Viatris's offerings.

Key Risk

If revenue growth exceeds expectations, it could challenge the current cautious outlook.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

The core debate this quarter revolves around the company's ability to sustain earnings growth amidst market challenges.

Bull Confirmed If

An EPS of $0.65 or higher would confirm the bull case and indicate strong operational performance.

Bear Confirmed If

An EPS below $0.50 would confirm the bear case and raise concerns about the company's profitability.

Pre-Earnings Positioning

Options Market

Implied Move

±16.20%

Historical Avg

±8.6%

Pricing rich

The options market is pricing in a significant move, indicating that investors expect volatility around the earnings report.

Options are pricing ±16.2% while VTRS has averaged ±8.6% over the last 8 prints — setup is pricing rich.

Detail

ATM IV

0.4%

30d HV

37.7%

Calls (50K)P/C Ratio: 0.46Puts (35K)

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If Viatris beats expectations, history suggests a positive stock reaction, averaging a +4.42% move.

In-Line / Cautious

If results are in line with expectations, the stock may see muted movement as investors await further guidance.

Miss

A miss could lead to a significant decline, with historical data showing an average drop of -15.21%.

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Any updates on new product launches and their expected impact on revenue.
2Management's commentary on cost management strategies.
3Insights into market share changes in key therapeutic areas.
4Details on international sales performance, particularly in emerging markets.
5Guidance on future earnings expectations and growth strategies.

See the full picture

AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.

No charge today · Auto-bills $8/mo after 7 days · Cancel anytime

More Earnings This Week

5 Reports

Aug3

ONBMO

ON Semiconductor Corporation

PreviewView

Aug3

LBMO

Company Snapshot

Viatris Inc. (VTRS) operates in the health care sector, focusing on pharmaceuticals....

Key Metrics to Watch

Earnings Per Share (EPS)

EPS is a key indicator of the company's profitability and performance, which investors will closely watch this quarter.

N/A

Revenue Growth

Revenue growth reflects the company's ability to expand its market presence and sales, critical for long-term success.

N/A

Wall Street expectations, options signals, track record, and call prep available with Pro.

VTRS Q2-2026 Earnings Preview

Context

Company Snapshot

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

88%

Avg EPS Surprise

+6.19%

Avg Stock Reaction

+1.97%

Last Quarter Recap

In Q1-2026, Viatris reported an EPS of $0.59, exceeding estimates by 13.46%. The stock reacted positively, gaining 9.03% the following day.

Management Promises & Guidance

Continued focus on expanding access to medicines.
Commitment to cost management and operational efficiency.
Plans to enhance product offerings and market presence.

Expectations

Wall Street Expectations

Overall, expectations for Viatris are mixed, with some analysts anticipating continued earnings growth while others express concerns over revenue stability.

Bull Case

If Viatris can maintain its positive EPS surprises and show strong revenue growth, it could significantly boost investor confidence and stock performance.

Bear Case

Conversely, if the company fails to meet expectations or shows signs of declining revenue, it could lead to a sharp drop in stock price.

Expectations

Two Questions That Matter

The print will turn on these two things.

What will the EPS be for Q2-2026?

Given the company's history of beating EPS estimates, this number will be crucial for investor sentiment.

How is revenue growth tracking compared to previous quarters?

Investors will closely monitor revenue growth to assess the company's market performance and sustainability.

Edge

What the Street Is Missing

Why consensus could be wrong

The Street may underestimate Viatris's ability to leverage its product portfolio for growth, especially in emerging markets.

Supporting Evidence

The company has consistently beaten EPS estimates, indicating stronger operational performance than anticipated.

Options pricing suggests a larger move than historical averages, indicating potential for significant stock movement.

Recent trends in the pharmaceutical sector show increasing demand for Viatris's offerings.

Key Risk

If revenue growth exceeds expectations, it could challenge the current cautious outlook.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

The core debate this quarter revolves around the company's ability to sustain earnings growth amidst market challenges.

Bull Confirmed If

An EPS of $0.65 or higher would confirm the bull case and indicate strong operational performance.

Bear Confirmed If

An EPS below $0.50 would confirm the bear case and raise concerns about the company's profitability.

Pre-Earnings Positioning

Options Market

Implied Move

±16.20%

Historical Avg

±8.6%

Pricing rich

The options market is pricing in a significant move, indicating that investors expect volatility around the earnings report.

Options are pricing ±16.2% while VTRS has averaged ±8.6% over the last 8 prints — setup is pricing rich.

Detail

ATM IV

0.4%

30d HV

37.7%

Calls (50K)P/C Ratio: 0.46Puts (35K)

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If Viatris beats expectations, history suggests a positive stock reaction, averaging a +4.42% move.

In-Line / Cautious

If results are in line with expectations, the stock may see muted movement as investors await further guidance.

Miss

A miss could lead to a significant decline, with historical data showing an average drop of -15.21%.

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Any updates on new product launches and their expected impact on revenue.
2Management's commentary on cost management strategies.
3Insights into market share changes in key therapeutic areas.
4Details on international sales performance, particularly in emerging markets.
5Guidance on future earnings expectations and growth strategies.